Insights into the future of first-line advanced hepatocellular carcinoma treatment

被引：0
|
作者：
Wong, Jeffrey Sum Lung [1 ]
Wong, Carmen Chak-Lui [2 ]
Sun, Frances Sze Kei [1 ]
Yau, Thomas [1 ,3 ]
机构：
[1] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[2] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Peoples R China
[3] Univ Hong Kong, Ctr Canc Med, Hong Kong, Peoples R China
来源：
LANCET ONCOLOGY | 2025年 / 26卷 / 02期
关键词：
ATEZOLIZUMAB; BEVACIZUMAB;
D O I：
10.1016/S1470-2045(24)00728-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：152 / 153
页数：2
相关论文
共 50 条
  • [21] Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
    Masnoon Saiyed
    Joshua Byrnes
    Tushar Srivastava
    Paul Scuffham
    Martin Downes
    Clinical Drug Investigation, 2020, 40 : 1167 - 1176
  • [22] A Network Meta-analysis of the Efficacy of Drug Therapy in First-line Treatment of Advanced Hepatocellular Carcinoma
    Wang, Xinchou
    Peng, Gaoyao
    Li, Jiangfa
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2024, 33 (01) : 94 - 101
  • [23] Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
    Saiyed, Masnoon
    Byrnes, Joshua
    Srivastava, Tushar
    Scuffham, Paul
    Downes, Martin
    CLINICAL DRUG INVESTIGATION, 2020, 40 (12) : 1167 - 1176
  • [24] Camrelizumab plus apatinib combined with TACE and cryoablation in the first-line treatment of advanced hepatocellular carcinoma.
    Xing, Wenge
    Guo, Zhi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Advanced Hepatocellular Carcinoma New effective Option in First-line Therapy: Lenvatinib
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (04) : 228 - 229
  • [26] First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials
    Cabibbo, Giuseppe
    Reig, Maria
    Celsa, Ciro
    Torres, Ferran
    Battaglia, Salvatore
    Enea, Marco
    Rizzo, Giacomo Emanuele Maria
    Petta, Salvatore
    Calvaruso, Vincenza
    Di Marco, Vito
    Craxi, Antonio
    Singal, Amit G.
    Bruix, Jordi
    Camma, Calogero
    LIVER CANCER, 2021, : 75 - 84
  • [27] FIRST-LINE IMMUNE CHECKPOINT INHIBITOR-BASED SEQUENTIAL THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: A RATIONALE FOR FUTURE TRIALS
    Cabibbo, G.
    Celsa, C.
    Battaglia, S.
    Enea, M. .
    Rizzo, G. E. M.
    Busacca, A.
    Petta, S.
    Calvaruso, V.
    Di Marco, V.
    Craxi, A.
    Camma, C.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S107 - S107
  • [28] New approaches to first-line treatment of advanced renal cell carcinoma
    George, Daniel J.
    Lee, Chung-Han
    Heng, Daniel
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [29] Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma
    Yau, Thomas
    Chan, Pierre
    Wong, Hilda
    Ng, Kelvin K.
    Chok, Siu-Ho
    Cheung, Tan-To
    Lam, Vincent
    Epstein, Richard J.
    Fan, Sheung-Tat
    Poon, Ronnie T. P.
    ONCOLOGY, 2007, 72 : 67 - 71
  • [30] Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma
    Vitale, Maria Giuseppa
    Nasso, Cecilia
    Oltrecolli, Marco
    Baldessari, Cinzia
    Fanelli, Martina
    Dominici, Massimo
    Sabbatini, Roberto
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1183 - 1192
12345